Development of a keratoacanthoma after topical photodynamic therapy with 5-aminolevulinic acid.
Since its FDA approval in 1999, photodynamic therapy (PDT) with topical 5-aminolevulinic acid has become an increasingly popular modality for the treatment of actinic keratosis (AKs). It is hoped that in addition to improving clinical signs and symptoms of AKs, PDT might prevent the development of skin cancer. We present a case of a patient developing a keratoacanthoma immediately following PDT for AKs.
Maydan
Elena
E
Department of Dermatology, Columbia University, New York, NY, USA.
Nootheti
Pavan K
PK
Goldman
Mitchel P
MP
D000287:Administration, Topical; D000622:Aminolevulinic Acid / Q000009:adverse effects*; D006801:Humans; D007636:Keratoacanthoma / Q000139:chemically induced*; D007642:Keratosis / Q000188:drug therapy*; D008297:Male; D008875:Middle Aged; D010778:Photochemotherapy / Q000009:adverse effects*; D017319:Photosensitizing Agents / Q000009:adverse effects*
D017319:Photosensitizing Agents; D000622:Aminolevulinic Acid